Therapeutic strategies in adrenoleukodystrophy

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Biochemistry

Background:

• Adrenoleukodystrophy (ALD) is an X-linked inherited condition resulting from ABCD1 gene mutations.
• These mutations impair the degradation of very long-chain fatty acids (VLCFAs), causing toxic accumulation.
• This accumulation triggers inflammation and cell death in various tissues, impacting the nervous system and adrenal glands.

Purpose of the Study:

• To summarize the current understanding of Adrenoleukodystrophy (ALD) pathology and therapeutic strategies.
• To highlight advancements in ALD detection and early intervention methods.
• To underscore the need for further research into genotype-phenotype correlations and disease triggers.

Main Methods:

• Review of existing literature on ALD genetics, pathophysiology, and clinical manifestations.
• Analysis of recent diagnostic advancements, including newborn screening and imaging techniques.
• Examination of current and emerging therapeutic approaches, focusing on gene mutation correction and downstream effects.

Main Results:

• ALD presents as a severe demyelinating disease in males or a progressive myelopathy in adults.
• Pathogenic mechanisms, including genotype-phenotype correlations and cerebral disease triggers, remain incompletely understood.
• Early detection through newborn screening is crucial for effective intervention with hematopoietic stem cell transplantation (HSCT).

Conclusions:

• Hematopoietic stem cell transplantation (HSCT) offers a potential treatment for early-stage cerebral ALD.
• Further research is essential to elucidate the complex pathophysiology of ALD and identify precise therapeutic targets.
• Improved diagnostic tools and screening programs enhance the potential for successful management of Adrenoleukodystrophy.